Hypertonic saline therapy in cystic fibrosis: Do population shifts caused by the osmotic sensitivity of infecting bacteria explain the effectiveness of this treatment?

Frontiers in Microbiology

Volumn 1, Issue NOV, 2010, Pages

  Williams, Huw D ^a   Behrends, Volker ^a   Bundy, Jacob G ^a   Ryall, Ben ^a   Zlosnik, James E A ^b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Alginate; Infective exacerbation; Metabolomics; mucA; Mucoid; Pseudomonas aeruginosa

Indexed keywords

EID: 84856902574     PISSN: None     EISSN: 1664302X     Source Type: Journal    
DOI: 10.3389/fmicb.2010.00120     Document Type: Article

References (68)

1. Aspedon, A., Palmer, K., and Whiteley, M. (2006). Microarray analysis of the osmotic stress response in Pseudomonas aeruginosa. J. Bacteriol. 188, 2721-2725.
2. Barbato, A., Frischer, T., Kuehni, C. E., Snijders, D., Azevedo, I., Baktai, G., Bartoloni, L., Eber, E., Escribano, A., Haarman, E., Hesselmar, B., Hogg, C., Jorissen, M., Lucas, J., Nielsen, K. G., O'Callaghan, C., Omran, H., Pohunek, P., Strippoli, M. P., and Bush, A. (2009). Primary ciliary dyskinesia: a consensus statement on diagnostic and treatment approaches in children. Eur. Respir. J. 34, 1264-1276.
3. Behrends, V., Ebbels, T. M., Williams, H. D., and Bundy, J. G. (2009). Time-resolved metabolic footprinting for nonlinear modeling of bacterial substrate utilization. Appl. Environ. Microbiol. 75, 2453-2463.
4. Behrends, V., Ryall, B., Wang, X., Bundy, J. G., and Williams, H. D. (2010). Metabolic profiling of Pseudomonas aeruginosa demonstrates that the anti-sigma factor MucA modulates osmotic stress tolerance. Mol. Biosyst. 6, 562-569.
5. Bendiak, G. N., and Ratjen, F. (2009). The approach to Pseudomonas aeruginosa in cystic fibrosis. Semin. Respir. Crit. Care Med. 30, 587-595.
6. Bjarnsholt, T., Jensen, P. O., Fiandaca, M. J., Pedersen, J., Hansen, C. R., Andersen, C. B., Pressler, T., Givskov, M., andHoiby, N. (2009). Pseudomonas aeruginosa biofilms in the respiratory tract of cystic fibrosis patients. Pediatr. Pulmonol. 44, 547-558.
7. Bjarnsholt, T., Tolker-Nielsen, T., Hoiby, N., and Givskov, M. (2010). Interference of Pseudomonas aeruginosa signalling and biofilm formation for infection control. Expert Rev. Mol. Med. 12, e11. doi:10.1017/S1462399410001420.
8. Boucher, J. C., Yu, H., Mudd, M. H., and Deretic, V. (1997). Mucoid Pseudomonas aeruginosa in cystic fibrosis: characterization of muc mutations in clinical isolates and analysis of clearance in a mouse model of respiratory infection. Infect. Immun. 65, 3838-3846.
9. Boucher, R. C. (2007). Cystic fibrosis: a disease of vulnerability to airway surface dehydration. Trends Mol. Med. 13, 231-240.
10. Campodonico, V. L., Gadjeva, M., Paradis-Bleau, C., Uluer, A., and Pier, G. B. (2008). Airway epithelial control of Pseudomonas aeruginosa infection in cystic fibrosis. Trends Mol. Med. 14, 120-133.
11. Campodonico, V. L., Llosa, N. J., Grout, M., Doring, G., Maira-Litran, T., and Pier, G. B. (2010). Evaluation of flagella and flagellin of Pseudomonas aeruginosa as vaccines. Infect. Immun. 78, 746-755.
12. Carterson, A. J., Morici, L. A., Jackson, D. W., Frisk, A., Lizewski, S. E., Jupiter, R., Simpson, K., Kunz, D. A., Davis, S. H., Fibro-Schurr, J. R., Hassett, D. J., and Schurr, M. J. (2004). The transcriptional regulator AlgR controls cyanide production in Pseudomonas aeruginosa. J. Bacteriol. 186, 6837-6844.
13. Collins, F. S. (1992). Cystic fibrosis: molecular biology and therapeutic implications. Science 256, 774-779.
14. Davies, J. C. (2006). Current and novel antimicrobial approaches. Prog. Respir. Res. 34, 180-186.
15. Davies, J. C., and Bilton, D. (2009). Bugs, biofilms, and resistance in cystic fibrosis. Respir. Care 54, 628-640.
16. Daviskas, E., Anderson, S. D., Jaques, A., and Charlton, B. (2010). Inhaled mannitol improves the hydration and surface properties of sputum in patients with cystic fibrosis. Chest 137, 861-868.
17. Dodge, J. A., Lewis, P. A., Stanton, M., and Wilsher, J. (2007). Cystic fibrosis mortality and survival in the UK: 1947-2003. Eur. Respir. J. 29, 522-526.
18. Donaldson, S. H., Bennett, W. D., Zeman, K. L., Knowles, M. R., Tarran, R., and Boucher, R. C. (2006). Mucus clearance and lung function in cystic fibrosis with hypertonic saline. N. Engl. J. Med. 354, 241-250.
19. Doring, G., Conway, S. P., Heijerman, H. G., Hodson, M. E., Hoiby, N., Smyth, A., and Touw, D. J. (2000). Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. Eur. Respir. J. 16, 749-767.
20. Elkins, M. R., Robinson, M., Rose, B. R., Harbour, C., Moriarty, C. P., Marks,G. B., Belousova, E. G., Xuan, W., and Bye, P. T. (2006). A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N. Engl. J. Med. 354, 229-240.
21. Firoved, A. M., Boucher, J. C., and Deretic, V. (2002). Global genomic analysis of AlgU (sigma(E))-dependent promoters (sigmulon) in Pseudomonas aeruginosa and implications for inflammatory processes in cystic fibrosis. J. Bacteriol. 184, 1057-1064.
22. Firoved, A. M., and Deretic, V. (2003). Microarray analysis of global gene expression in mucoid Pseudomonas aeruginosa. J. Bacteriol. 185, 1071-1081.
23. Foweraker, J. (2009). Recent advances in the microbiology of respiratory tract infection in cystic fibrosis. Br. Med. Bull. 89, 93-110.
24. Gibson, R. L., Burns, J. L., and Ramsey, B. W. (2003). Pathophysiology and management of pulmonary infections in cystic fibrosis. Am. J. Respir. Crit. Care Med. 168, 918-951.
25. Goss, C. H., and Burns, J. L. (2007). Exacerbations in cystic fibrosis. 1: epidemiology and pathogenesis. Thorax 62, 360-367.
26. Govan, J. R., Brown, A. R., and Jones, A. M. (2007). Evolving epidemiology of Pseudomonas aeruginosa and the Burkholderia cepacia complex in cystic fibrosis lung infection. Future Microbiol. 2, 153-164.
27. Govan, J. R., and Deretic, V. (1996). Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia. Microbiol. Rev. 60, 539-574.
28. Hassett, D. J., Korfhagen, T. R., Irvin, R. T., Schurr, M. J., Sauer, K., Lau, G. W., Sutton, M. D., Yu, H., and Hoiby, N. (2010). Pseudomonas aeruginosa biofilm infections in cystic fibrosis: insights into pathogenic processes and treatment strategies. Expert Opin. Ther. Targets 14, 117-130.
29. Hassett, D. J., Sutton, M. D., Schurr, M. J., Herr, A. B., Caldwell, C. C., and Matu, J. O. (2009). Pseudomonas aeruginosa hypoxic or anaerobic biofilm infections within cystic fibrosis airways. Trends Microbiol. 17, 130-138.
30. Havasi, V., Hurst, C. O., Briles, T. C., Yang, F., Bains, D. G., Hassett, D. J., and Sorscher, E. (2008). Inhibitory effects of hypertonic saline on P. aeruginosa motility. J. Cyst. Fibros. 7, 267-269.
31. Hentzer, M., Teitzel, G. M., Balzer, G. J., Heydorn, A., Molin, S., Givskov, M., and Parsek, M. R. (2001). Alginate overproduction affects Pseudomonas aeruginosa biofilm structure and function. J. Bacteriol. 183, 5395-5401.
32. Hershberger, C. D., Ye, R. W., Parsek, M. R., Xie, Z. D., and Chakrabarty, A. M. (1995). The algT (algU) gene of Pseudomonas aeruginosa, a key regulator involved in alginate biosynthesis, encodes an alternative sigma factor (sigma E). Proc. Natl. Acad. Sci. U.S.A. 92, 7941-7945.
33. Hoiby, N., Bjarnsholt, T., Givskov, M., Molin, S., and Ciofu, O. (2010). Antibiotic resistance of bacterial biofilms. Int. J. Antimicrob. Agents 35, 322-332.
34. Jaques, A., Daviskas, E., Turton, J. A., McKay, K., Cooper, P., Stirling, R. G., Robertson, C. F., Bye, P. T., Lesouef, P. N., Shadbolt, B., Anderson, S. D., and Charlton, B. (2008). Inhaled mannitol improves lung function in cystic fibrosis. Chest 133, 1388-1396.
35. Jones, A. P., and Wallis, C. (2003). Dornase alfa for cystic fibrosis. Cochrane Database Syst. Rev. CD001127.
36. King, M., Dasgupta, B., Tomkiewicz, R. P., and Brown, N. E. (1997). Rheology of cystic fibrosis sputum after in vitro treatment with hypertonic saline alone and in combination with recombinant human deoxyribonuclease I. Am. J. Respir. Crit. Care Med. 156, 173-177.
37. Kirov, S. M., Webb, J. S., O'May C. Y., Reid, D. W., Woo, J. K., Rice, S. A., and Kjelleberg, S. (2007). Biofilm differentiation and dispersal in mucoid Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Microbiology 153(Pt 10), 3264-3274.
38. Levin, M. H., Sullivan, S., Nielson, D., Yang, B., Finkbeiner, W. E., and Verkman, A. S. (2006). Hypertonic saline therapy in cystic fibrosis: evidence against the proposed mechanism involvfibroing aquaporins. J. Biol. Chem. 281, 25803-25812.
39. Livraghi, A., and Randell, S. H. (2007). Cystic fibrosis and other respiratory diseases of impaired mucus clearance. Toxicol. Pathol. 35, 116-129.
40. Lyczak, J. B., Cannon, C. L., and Pier, G. B. (2002). Lung infections associated with cystic fibrosis. Clin. Microbiol. Rev. 15, 194-222.
41. Martin, D. W., Schurr, M. J., Mudd, M. H., Govan, J. R., Holloway, B. W., and Deretic, V. (1993). Mechanism of conversion to mucoidy in Pseudomonas aeruginosa infecting cystic fibrosis patients. Proc. Natl. Acad. Sci. U.S.A. 90, 8377-8381.
42. Mathee, K., Ciofu, O., Sternberg, C., Lindum, P. W., Campbell, J. I., Jensen, P., Johnsen, A. H., Givskov, M., Ohman, D. E., Molin, S., Høiby, N., and Kharazmi, A. (1999). Mucoid conversion of Pseudomonas aeruginosa by hydrogen peroxide: a mechanism for virulence activation in the cystic fibrosis lung. Microbiology 145, 1349-1357.
43. Matsui, H., Grubb, B. R., Tarran, R., Randell, S. H., Gatzy, J. T., Davis, C. W., and Boucher, R. C. (1998). Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease. Cell 95, 1005-1015.
44. Minasian, C., Wallis, C., Metcalfe, C., and Bush, A. (2008). Bronchial provocation testing with dry powder mannitol in children with cystic fibrosis. Pediatr. Pulmonol. 43, 1078-1084.
45. Moreau-Marquis, S., Stanton, B. A., and O'Toole, G. A. (2008). Pseudomonas aeruginosa biofilm formation in the cystic fibrosis airway. Pulm. Pharmacol. Ther. 21, 595-599.
46. Morris, A. E., Liggitt, H. D., Hawn, T. R., and Skerrett, S. J. (2009). Role of Toll-like receptor 5 in the innate immune response to acute P. aeruginosa pneumonia. Am. J. Physiol. Lung Cell. Mol. Physiol. 297, L1112-L1119.
47. Murray, T. S., Egan, M., and Kazmierczak, B. I. (2007). Pseudomonas aeruginosa chronic colonization in cystic fibrosis patients. Curr. Opin. Pediatr. 19, 83-88.
48. Noone, P. G., Leigh, M. W., Sannuti, A., Minnix, S. L., Carson, J. L., Hazucha, M., Zariwala, M. A., and Knowles, M. R. (2004). Primary ciliary dyskinesia: diagnostic and phenotypic features. Am. J. Respir. Crit. Care Med. 169, 459-467.
49. Ramsey, D. M., and Wozniak, D. J. (2005). Understanding the control of Pseudomonas aeruginosa alginate synthesis and the prospects for management of chronic infections in cystic fibrosis. Mol. Microbiol. 56, 309-322.
50. Raoust, E., Balloy, V., Garcia-Verdugo, I., Touqui, L., Ramphal, R., and Chignard,M. (2009). Pseudomonas aeruginosa LPS or flagellin are sufficient to activate TLR-dependent signaling in murine alveolar macrophages and airway epithelial cells. PLoS ONE 4, e7259. doi:10.1371/journal.pone.0007259.
51. Ratjen, F. (2001). Changes in strategies for optimal antibacterial therapy in cystic fibrosis. Int. J. Antimicrob. Agents 17, 93-96.
52. Ratjen, F. (2006). Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis. Curr. Opin. Pulm. Med. 12, 428-432.
53. Ratjen, F., and Doring, G. (2003). Cystic fibrosis. Lancet 361, 681-689.
54. Reid, D. W., Kirov, S. M., Webb, J. S., Carroll, V., Kjelleberg, S., Champion, A., and Sanderson, K. (2006). Biofilm dispersal and exacerbations of cystic fibrosis lung disease. Pediatr. Pulmonol. 41, 1254; author reply 1255.
55. Robinson, M., Daviskas, E., Eberl, S., Baker, J., Chan, H. K., Anderson, S. D., and Bye, P. T. (1999). The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study. Eur. Respir. J. 14, 678-685.
56. Robinson, M., Hemming, A. L., Regnis, J. A., Wong, A. G., Bailey, D. L., Bautovich, G. J., King, M., and Bye, P. T. (1997). Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. Thorax 52, 900-903.
57. Robinson, M., Regnis, J. A., Bailey, D. L., King, M., Bautovich, G. J., and Bye, P. T. (1996). Effect of hypertonic saline, amiloride, and cough on mucociliary clearance in patients with cystic fibrosis. Am. J. Respir. Crit. Care Med. 153, 1503-1509.
58. Rowen, D. W., and Deretic, V. (2000). Membrane-to-cytosol redistribution of ECF sigma factor AlgU and conversion to mucoidy in Pseudomonas aeruginosa isolates from cystic fibrosis patients. Mol. Microbiol. 36, 314-327.
59. Schurr, M. J., Yu, H., Martinez-Salazar, J. M., Boucher, J. C., and Deretic, V. (1996). Control of AlgU, a member of the sigma E-like family of stress sigma factors, by the negative regulators MucA and MucB and Pseudomonas aeruginosa conversion to mucoidy in cystic fibrosis. J. Bacteriol. 178, 4997-5004.
60. Schwarzmann, S., and Boring, J. R. (1971). Antiphagocytic effect of slime from a mucoid strain of Pseudomonas aeruginosa. Infect. Immun. 3, 762-767.
61. Sibley, C. D., Parkins, M. D., Rabin, H. R., Duan, K., Norgaard, J. C., and Surette, M. G. (2008). A polymicrobial perspective of pulmonary infections exposes an enigmatic pathogen in cystic fibrosis patients. Proc. Natl. Acad. Sci. U.S.A. 105, 15070-15075.
62. Smith, J. J., Travis, S. M., Greenberg, E. P., and Welsh, M. J. (1996). Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface fluid. Cell 85, 229-236.
63. Tunney, M. M., Field, T. R., Moriarty, T. F., Patrick, S., Doering, G., Muhlebach, M. S., Wolfgang, M. C., Boucher, R., Gilpin, D. F., McDowell, A., and Elborn, J. S. (2008). Detection of anaerobic bacteria in high numbers in sputum from patients with cystic fibrosis. Am. J. Respir. Crit. Care Med. 177, 995-1001.
64. VanDevanter, D. R., and Van Dalfsen, J. M. (2005). How much do Pseudomonas biofilms contribute to symptoms of pulmonary exacerbation in cystic fibrosis? Pediatr. Pulmonol. 39, 504-506.
65. Wark, P., and McDonald, V. M. (2009). Nebulised hypertonic saline for cystic fibrosis. Cochrane Database Syst. Rev. CD001506.
66. Whitchurch, C. B., Alm, R. A., and Mattick, J. S. (1996). The alginate regulator AlgR and an associated sensor FimS are required for twitching motility in Pseudomonas aeruginosa. Proc. Natl. Acad. Sci. U.S.A. 93, 9839-9843.
67. Wood, L. F., Leech, A. J., and Ohman, D. E. (2006). Cell wall-inhibitory antibiotics activate the alginate biosynthesis operon in Pseudomonas aeruginosa: roles of sigma (AlgT) and the AlgW and Prc proteases. Mol. Microbiol. 62, 412-426.
68. Wu, W., Badrane, H., Arora, S., Baker, H. V., and Jin, S. (2004). MucA-mediated coordination of type III secretion and alginate synthesis in Pseudomonas aeruginosa. J. Bacteriol. 186, 7575-7585.